Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:29 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia
NCT06176235 · Peking University People's Hospital · PHASE2 · withdrawn · last registry update 2025-08-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Trial withdrawn due to substantial protocol amendments invalidating the original design. With no participants enrolled, this aligns with WHO-ICTRP guidelines. Recruitment has ceased, and the revised protocol has been re-registered as NCT07065968.” | – | Registry record, Peking University People's Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DHODH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-09-23Phase 3 first posted: University Hospital, Montpellier, Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons) + Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) (NCT07189325)
- 2025-08-17Also stopped (withdrawn): University Hospital, Antwerp, tolerogenic dendritic cells (tolDC) + Standard-of-care (NCT06715605)
- 2025-06-18Results posted on the registry: Sanofi, Tolebrutinib + Teriflunomide (NCT04410978)
- 2025-06-18Results posted on the registry: Sanofi, Tolebrutinib + Teriflunomide HMR1726 (NCT04410991)
- 2025-06-12Results posted on the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338022)
- 2025-06-12Also stopped (terminated): Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338022)
- 2025-03-21Also stopped (terminated): Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338061)
- 2025-01-14Results posted on the registry: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338061)
- 2024-11-13Results posted on the registry: Immunic AG, IMU-838 (NCT04379271)
- 2024-10-29Phase 3 first posted: University Hospital, Strasbourg, France, treatment withdrawal + Usual DMT continuation (NCT06663189)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision